FACIT, a commercialization venture firm focused on advancing Ontario’s top-tier oncology innovations, announced new follow-on investments in start-ups Xpan Inc. (“Xpan”) and Nanology Labs (“Nanology”). Spun out of the University of Toronto, both start-ups have previously received funding through FACIT’s proof-of-concept Prospects Fund that enabled the companies to address key commercialization challenges. Upon successfully achieving initial business targets, these start-ups and their respective technologies have been elevated to an equity-based investment through FACIT’s seed stage Compass Rose Fund.
Nanology has developed a first-in-class theranostic agent enabling real-time tumor detection and radio-sensitization. In animal models, this agent is safer and more sensitive than MRI contrast agents currently available. It simultaneously oxygenates the tumor area leading to an improvement in radiation therapy efficacy. “FACIT’s follow-on investment is critical in enabling our technology to reach its next inflection point, moving closer to the clinic and positioning our company for further investment,” said Dr. Mohammad Ali Amini, Co-Founder and CEO of Nanology.
© 2019 nanologylabs.com